Health Catalyst (NASDAQ:HCAT – Get Free Report) and Schrodinger (NASDAQ:SDGR – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.
Analyst Ratings
This is a summary of recent recommendations and price targets for Health Catalyst and Schrodinger, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Health Catalyst | 1 | 5 | 0 | 0 | 1.83 |
| Schrodinger | 1 | 3 | 4 | 0 | 2.38 |
Health Catalyst currently has a consensus price target of $2.01, indicating a potential upside of 43.97%. Schrodinger has a consensus price target of $26.67, indicating a potential downside of 5.06%. Given Health Catalyst’s higher possible upside, analysts plainly believe Health Catalyst is more favorable than Schrodinger.
Risk & Volatility
Health Catalyst has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500.
Insider and Institutional Ownership
85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 19.4% of Health Catalyst shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Health Catalyst and Schrodinger’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Health Catalyst | -74.24% | -4.84% | -2.02% |
| Schrodinger | -22.02% | -18.12% | -9.07% |
Earnings & Valuation
This table compares Health Catalyst and Schrodinger”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Health Catalyst | $272.20 million | 0.39 | -$177.97 million | ($2.83) | -0.49 |
| Schrodinger | $269.20 million | 7.70 | -$103.26 million | ($0.79) | -35.55 |
Schrodinger has lower revenue, but higher earnings than Health Catalyst. Schrodinger is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.
About Health Catalyst
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions are designed to help providers use clinical, operational, and financial data to support decision-making and improve care delivery. The company’s offerings include a data platform that brings together information from multiple sources, analytics applications for healthcare workflows, and professional services. These services can include implementation, data management, and support for organizations developing and applying analytics programs.
About Schrodinger
Schrödinger, Inc. develops computational software used to support drug discovery and materials research. Its platform applies physics-based modeling, computational chemistry and machine learning to help researchers analyze molecular properties and identify promising candidates. The company’s tools are used by pharmaceutical and biotechnology companies, academic institutions and other research organizations. Alongside software sales and subscriptions, Schrödinger works with partners on drug discovery programs and advances a portfolio of its own therapeutic candidates.
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
